--- title: "BioMarin Pharmaceutical (BMRN): news, pipeline and catalysts" url: "https://aibio.space/companies/biomarin-pharmaceutical/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "BioMarin Pharmaceutical news for investors: BioMarin develops and sells medicines for rare genetic diseases, led by the growth drug Voxzogo for…" --- Desk view · Opinion · Updated Oct 22, 2026 ## BioMarin bets on breadth while Voxzogo faces its first rival BioMarin is a profitable rare disease company that used debt to pay for growth through Amicus, and Voxzogo is near $1 billion a year with a second indication filed. The weak spot is the pipeline, where its most recent late-stage bet failed and the next readouts sit in 2027 and 2028. Read the full desk view aibio.space Investor Rank · Opinion **7** /10 Positive view A profitable rare disease company with Voxzogo near $1 billion, but Amicus debt, a new Voxzogo rival and a recent late-stage failure weigh on it. - **Technology**: 2/2 - **Odds**: 2/2 - **Balance sheet**: 1/2 - **Risk**: 1/2 - **Momentum**: 1/2 Opinion only. The Investor Rank is aibio.space's opinion of the company's business position, drawn from the public sources on this page. It is not a recommendation to buy, sell or hold any security and it is not investment advice. It does not consider the share price, valuation or your circumstances, and it can change at any time. Payments from companies never affect it. [How the rank works](https://aibio.space/disclosures/#rank). - **Technology**: **Proven commercial platform.** Nine marketed rare disease drugs, with Voxzogo approved in several regions and positive phase 3 data in hypochondroplasia. - **Odds**: **High for near-term filings.** Label expansions of approved drugs carry high approval rates; ALE1 and BMN 351 face normal early-stage odds. - **Balance sheet**: **Levered after Amicus.** Cash of $874 million against about $4.19 billion of debt at June 30, with a target of leverage below 2.5x by mid-2027. - **Main risk**: **Voxzogo competition.** A once-weekly rival launched in the U.S. in 2026 and has started to take patients. - **Watch next**: **Third-quarter results.** Updated guidance with Alesta charges and a status report on the hypochondroplasia filing. ## Top news on BioMarin 1. 2026-01-29 Financings [BioMarin prices $850 million of 5.5% notes to help fund its $4.8 billion Amicus purchase](https://aibio.space/news/biomarin-prices-850-million-5-5-percent-notes-help-fund-4-8-billion/) The senior notes due 2034 priced at par and will sit in escrow until the deal closes. BioMarin also completed syndication of a $2 billion term loan B. ## Dates **With Q3 2026 results** Updated full-year 2026 guidance including the Alesta deal, and an update on the hypochondroplasia sNDA [Source](https://www.sec.gov/Archives/edgar/data/0001048477/000104847726000019/bmrn-20261006.htm) **By year-end 2026** BMN 351 Duchenne program update [Source](https://www.sec.gov/Archives/edgar/data/0001048477/000104847726000015/earningsrelease-6aug26ex991.htm) **February 28, 2027** FDA action date on full approval of Voxzogo in achondroplasia [Source](https://www.biomarin.com/?p=12083) **2027** Potential Voxzogo launch in hypochondroplasia and BMN 333 data update [Source](https://www.sec.gov/Archives/edgar/data/0001048477/000104847726000015/earningsrelease-6aug26ex991.htm) **2028** BMN 820 phase 3 data in FSGS [Source](https://www.sec.gov/Archives/edgar/data/0001048477/000104847726000015/earningsrelease-6aug26ex991.htm) ## The money Cash and cash equivalents of $874.0 million at June 30, 2026, with no short- or long-term investments, against about $4.19 billion of debt. BioMarin targets gross leverage below 2.5x by mid-2027. [Source](https://www.sec.gov/Archives/edgar/data/0001048477/000104847726000015/earningsrelease-6aug26ex991.htm) Total revenue of $990 million in Q2 2026, up 20% year over year, including Voxzogo sales of $253 million. 2026 guidance: $3.875 billion to $3.925 billion. [Source](https://www.sec.gov/Archives/edgar/data/0001048477/000104847726000015/earningsrelease-6aug26ex991.htm) ## Risks on the record - Ascendis's once-weekly Yuviwel won U.S. accelerated approval in achondroplasia in 2026; about 10% of U.S. Voxzogo patients switched in the first six months. [Source](https://www.nasdaq.com/articles/biomarin-pharmaceutical-q2-earnings-call-highlights) - Debt of about $4.19 billion after the Amicus deal, with about $200 million a year in expected interest. [Source](https://www.sec.gov/Archives/edgar/data/0001048477/000104847726000015/earningsrelease-6aug26ex991.htm) - BMN 401, the main late-stage asset outside Voxzogo, failed a phase 3 co-primary endpoint and was discontinued. [Source](https://www.biomarin.com/wp-content/uploads/2026/07/Update-on-BMN-401-Program.pdf) ## Questions investors ask ### What is aibio.space's Investor Rank for BioMarin Pharmaceutical? 7 out of 10, our positive view. A profitable rare disease company with Voxzogo near $1 billion, but Amicus debt, a new Voxzogo rival and a recent late-stage failure weigh on it. This is opinion only, not a recommendation to buy, sell or hold, and it does not consider the share price or valuation. [Source](https://aibio.space/disclosures/#rank) ### What is Voxzogo approved for? Voxzogo (vosoritide) is approved to increase linear growth in children with achondroplasia and open growth plates in the U.S., Japan and Australia, and in the EU for children 4 months and older. The U.S. approval is an accelerated approval; an application for full approval has a target action date of Feb. 28, 2027. [Source](https://www.biomarin.com/?p=12083) ### Did BioMarin's Voxzogo work in hypochondroplasia? Yes. In the phase 3 CANOPY-HCH-3 trial of 80 children, Voxzogo increased annualized growth velocity by 2.33 cm per year versus placebo at 52 weeks (p<0.0001). BioMarin has filed with the FDA and has said a launch could come in 2027. [Source](https://www.biomarin.com/?p=12083) ### How much did BioMarin pay for Amicus Therapeutics? BioMarin paid $14.50 per share in cash, an equity value of about $4.8 billion, and closed the deal on April 27, 2026. It reported cash paid, net of cash acquired, of about $5.07 billion. [Source](https://www.biopharmawatch.com/news/BMRN/investors-media-traci-mccarty-marni-kottle-biomarin-pharmaceutical-inc-biomarin-pharmaceut-bmrn-20260427) ### Why did BioMarin discontinue BMN 401? In the phase 3 ENERGY 3 trial in children with ENPP1 deficiency, BMN 401 raised plasma PPi but did not improve rickets on the RGI-C X-ray score, one of two co-primary endpoints. BioMarin said the results left it without a path to approval and ended the program in all indications. [Source](https://www.biomarin.com/wp-content/uploads/2026/07/Update-on-BMN-401-Program.pdf) ### What is BioMarin's 2026 revenue guidance? In August 2026 BioMarin guided to total 2026 revenue of $3.875 billion to $3.925 billion, with Voxzogo at $1.0 billion to $1.05 billion. It plans to update guidance with third-quarter results to reflect the Alesta acquisition. [Source](https://www.sec.gov/Archives/edgar/data/0001048477/000104847726000015/earningsrelease-6aug26ex991.htm) ### What is the latest BioMarin Pharmaceutical (BMRN) stock news? Our latest story on BioMarin Pharmaceutical, dated Jan 29, 2026: "BioMarin prices $850 million of 5.5% notes to help fund its $4.8 billion Amicus purchase". The senior notes due 2034 priced at par and will sit in escrow until the deal closes. BioMarin also completed syndication of a $2 billion term loan B. [Source](https://aibio.space/news/biomarin-prices-850-million-5-5-percent-notes-help-fund-4-8-billion/) ### What is BioMarin Pharmaceutical's latest stock offering or financing news? Our latest financing story, dated Jan 29, 2026: "BioMarin prices $850 million of 5.5% notes to help fund its $4.8 billion Amicus purchase". The senior notes due 2034 priced at par and will sit in escrow until the deal closes. BioMarin also completed syndication of a $2 billion term loan B. [Source](https://aibio.space/news/biomarin-prices-850-million-5-5-percent-notes-help-fund-4-8-billion/) ### What is BioMarin Pharmaceutical's market cap? We do not publish live share prices. In its annual report, BioMarin Pharmaceutical Inc. put the market value of shares held by non-affiliates (public float) at $6.70 billion as of Jun 30, 2025. Source ### Is BioMarin Pharmaceutical a smaller reporting company? SEC records list BioMarin Pharmaceutical Inc.'s filer category as: Large accelerated filer. Source ### Where is BioMarin Pharmaceutical headquartered? SEC records list its business address as 105 DIGITAL DRIVE, NOVATO, CA, 94949. Source ### When does BioMarin Pharmaceutical's fiscal year end? BioMarin Pharmaceutical Inc.'s fiscal year ends on December 31, per SEC records. Source ### What did BioMarin Pharmaceutical last file with the SEC? Its most recent filing in our record is an 8-K filed 2026-10-06. All of its filings are on SEC EDGAR. [Source](https://www.sec.gov/Archives/edgar/data/1048477/000104847726000019/bmrn-20261006.htm) ### What industry is BioMarin Pharmaceutical in? Its SEC industry code (SIC 2834) is Pharmaceutical Preparations. Source ### How can I follow BioMarin Pharmaceutical (BMRN) news? Press Follow on this page to add BioMarin Pharmaceutical to your Following list, or subscribe to the aibio.space newsletter. We have published 1 story naming BioMarin Pharmaceutical so far, in Financings. Source ## Legal and investor matters Checked against BioMarin Pharmaceutical filings and press releases. Allegations are allegations; nothing here is a finding of fault. Reviewed Oct 25, 2026. The 10-Q filed 2026-08-06 for the period ended 2026-06-30 lists Part II, Item 1 (Legal Proceedings) as "None." This covers that filing only; the same 10-Q discloses a DOJ subpoena in its notes. [Source](https://www.sec.gov/Archives/edgar/data/1048477/000104847726000016/bmrn-20260630.htm) 1. 2026-09-24 Litigation BioMarin and Ascendis sign settlement and license agreement to resolve patent proceedings BioMarin and Ascendis signed a Settlement and License Agreement on 2026-09-24, consistent with a binding term sheet reported on 2026-08-31 that resolves all pending proceedings over BioMarin patent rights. Ascendis gets a non-exclusive license for TransCon CNP and pays BioMarin 20% of annual U.S. net sales and 18% in the European Union, Brazil and South Korea until May 2030. The parties will dismiss pending litigation with prejudice. Status: settled [BioMarin Form 8-K filed 2026-09-30](https://www.sec.gov/Archives/edgar/data/1048477/000162828026063981/bmrn-20260924.htm) 2. 2026-09-15 Other BioMarin discontinues VOXZOGO development in Noonan syndrome On 2026-09-15 BioMarin announced its decision to discontinue development of VOXZOGO for children with Noonan syndrome. The company said it assessed the feasibility of the study and the current treatment landscape. It stated that the decision was not related to the safety or efficacy of VOXZOGO. [BioMarin Form 8-K filed 2026-09-15](https://www.sec.gov/Archives/edgar/data/1048477/000162828026061973/bmrn-20260915.htm) 3. 2026-08-31 Other BioMarin completes Alesta Therapeutics acquisition for $275 million upfront BioMarin agreed on 2026-08-17 to acquire Alesta Therapeutics B.V., a private Dutch company, for $275 million upfront in cash plus up to $215 million in development milestone payments. BioMarin completed the share purchase on 2026-08-31, and Alesta is now a wholly owned subsidiary. [BioMarin Form 8-K filed 2026-09-01](https://www.sec.gov/Archives/edgar/data/1048477/000119312526377696/d110660d8k.htm) 4. 2026-08-06 Regulatory BioMarin discloses DOJ subpoena on VIMIZIM and NAGLAZYME testing programs BioMarin's 10-Q says it received a U.S. Department of Justice subpoena, first disclosed in its 10-K for 2023, requesting documents on sponsored testing programs for VIMIZIM and NAGLAZYME. The company says it has produced the requested documents and is cooperating fully. It says it cannot give assurances about the outcome of the DOJ investigation. Status: pending [BioMarin Form 10-Q filed 2026-08-06](https://www.sec.gov/Archives/edgar/data/1048477/000104847726000016/bmrn-20260630.htm) 5. 2026-04-27 Other BioMarin completes Amicus Therapeutics acquisition at $14.50 per share BioMarin completed its merger with Amicus Therapeutics on 2026-04-27 under the merger agreement dated 2025-12-19. Each Amicus share was converted into the right to receive $14.50 in cash, and Amicus became a wholly owned subsidiary. A French foreign direct investment clearance was granted on 2026-04-23. [BioMarin Form 8-K filed 2026-04-27](https://www.sec.gov/Archives/edgar/data/1048477/000119312526179243/d113922d8k.htm) 6. 2026-03-16 Other BioMarin halts VOXZOGO Phase 2 dosing in three conditions after bone events On 2026-03-16 BioMarin announced it would discontinue dosing and enrollment in its Phase 2 trials of VOXZOGO in Turner syndrome, SHOX deficiency and ACAN deficiency. The decision followed several slipped capital femoral epiphysis events in two ongoing investigator-sponsored trials. BioMarin said no such events had been observed in its own Phase 2 trials in these conditions. [BioMarin Form 8-K filed 2026-03-16](https://www.sec.gov/Archives/edgar/data/1048477/000119312526107314/d114815d8k.htm) 7. 2026-02-12 Financing BioMarin completes $850 million notes placement to fund Amicus deal On 2026-02-12 BioMarin completed a private placement of $850 million aggregate principal amount of 5.500% senior notes. It said it intends to use the proceeds, together with borrowings under a new $2 billion senior secured term loan B facility and an $800 million senior secured term loan A facility and cash on hand, to fund the pending acquisition of Amicus Therapeutics and related fees. [BioMarin Form 8-K filed 2026-02-12](https://www.sec.gov/Archives/edgar/data/1048477/000119312526048736/d63881d8k.htm) 8. 2025-05-16 Other BioMarin agrees to acquire Inozyme Pharma at $4.00 per share On 2025-05-16 BioMarin entered into a merger agreement with Inozyme Pharma. Under the agreement, a BioMarin subsidiary was to begin a cash tender offer no later than 2025-06-02 for all outstanding Inozyme shares at $4.00 per share. The offer was to remain open for 20 business days, subject to extension and to the satisfaction of conditions. [BioMarin Form 8-K filed 2025-05-16](https://www.sec.gov/Archives/edgar/data/1048477/000119312525121296/d833625d8k.htm) ## Pipeline | Program | Indication | Stage | |---|---|---| | Voxzogo (vosoritide) | Hypochondroplasia | sNDA submitted to FDA [Source](https://www.biomarin.com/?p=12083) | | Voxzogo (vosoritide) | Achondroplasia (full approval) | sNDA under FDA review, PDUFA Feb. 28, 2027 [Source](https://www.biomarin.com/?p=12083) | | BMN 333 (long-acting CNP) | Achondroplasia | Phase 2/3 enrolling [Source](https://www.sec.gov/Archives/edgar/data/0001048477/000104847726000015/earningsrelease-6aug26ex991.htm) | | BMN 820 (formerly DMX-200) | Focal segmental glomerulosclerosis | Phase 3 (ACTION 3) [Source](https://www.sec.gov/Archives/edgar/data/0001048477/000104847726000015/earningsrelease-6aug26ex991.htm) | | BMN 351 | Duchenne muscular dystrophy | Phase 1/2 [Source](https://www.sec.gov/Archives/edgar/data/0001048477/000104847726000015/earningsrelease-6aug26ex991.htm) | | ALE1 | Hypophosphatasia | Phase 1/2a [Source](https://www.biomarin.com/?p=12067) | Opinion · Devil's advocate ## Fact-check-o-meter Some gaps BioMarin's messaging mostly matches its filings, but the guidance raise and the Voxzogo pipeline story have moved since August The August release disclosed that the revenue jump came from the Amicus acquisition, and the 10-Q backs the numbers. The gaps are about timing and framing: raised non-GAAP EPS guidance that excluded the later Alesta charge, a Voxzogo growth story that has already dropped development in Noonan syndrome, and a hypochondroplasia filing built on a small trial. The only legal item is a DOJ subpoena, with no securities litigation disclosed. 1. Press release vs filing · weight medium Raised EPS guidance predates a large new charge **The company said:** "Stronger Growth Expectations Drive Increased Guidance for Full-year 2026 Total Revenues, VOXZOGO ® , and Non-GAAP Diluted Earnings Per Share (EPS)" [source](https://www.sec.gov/Archives/edgar/data/1048477/000104847726000015/earningsrelease-6aug26ex991.htm) **The record says:** The October 8-K says BioMarin expects "approximately $283 million of acquired in-process research and development (IPR&D) expense", "an unfavorable impact of approximately $1.50 to both GAAP Diluted earnings per share (EPS) and Non-GAAP Diluted EPS for the third quarter of 2026", and that the August 6 guidance "did not reflect the acquisition of Alesta". [source](https://www.sec.gov/Archives/edgar/data/1048477/000104847726000019/bmrn-20261006.htm) **Our view:** The August release raised non-GAAP EPS guidance. About two months later the 8-K said the Alesta acquisition, announced after the August release and completed August 31, would have an unfavorable impact of about $1.55 a share on full-year 2026 GAAP and non-GAAP EPS, which the August guidance did not reflect. The company said it expects to update guidance with third-quarter results. 2. Press release vs filing · weight low Revenue growth is mostly bought, not organic **The company said:** "Second Quarter 2026 Total Revenues Increased 20% Year-over-year to $990 million" [source](https://www.sec.gov/Archives/edgar/data/1048477/000104847726000015/earningsrelease-6aug26ex991.htm) **The record says:** The same release says the increase was "primarily driven by revenues from GALAFOLD and POMBILITI + OPFOLDA, which were acquired from Amicus on April 27, 2026", that VOXZOGO sales were $253 million against $221 million (up 14%), and that "GAAP Net Income for the second quarter of 2026 decreased to $45 million compared to $241 million for the same period in 2025." [source](https://www.sec.gov/Archives/edgar/data/1048477/000104847726000015/earningsrelease-6aug26ex991.htm) **Our view:** The release is open about the source of growth, so this is a framing point, not a contradiction. A 20% headline sits next to a 14% Voxzogo increase and a large fall in GAAP profit after acquisition and interest costs. 3. Press release vs filing · weight medium Voxzogo's second indication, and the one dropped **The company said:** "Adding to this momentum is the opportunity to advance our second potential indication with VOXZOGO, hypochondroplasia, based on recent pivotal data that exceeded our expectations." [source](https://www.sec.gov/Archives/edgar/data/1048477/000104847726000015/earningsrelease-6aug26ex991.htm) **The record says:** The 10-Q filed the same day lists hypochondroplasia, idiopathic short stature and Noonan syndrome as areas BioMarin is "continuing to advance". On September 15, 2026 an 8-K reported "its decision to discontinue development of VOXZOGO for children with Noonan syndrome" and said "This decision was not related to the safety or efficacy of VOXZOGO." [source](https://www.sec.gov/Archives/edgar/data/1048477/000162828026061973/bmrn-20260915.htm) **Our view:** The Voxzogo expansion story is now narrower than the August documents described, and the 8-K gives the reasons as the feasibility of the study and the current treatment landscape, and says the decision was not related to safety or efficacy. The 10-Q risk factor ties Voxzogo to larger patient populations, and one of the three conditions it names is now dropped. 4. Science · weight medium Hypochondroplasia rests on a small, 52-week growth trial **The company said:** "the Phase 3 CANOPY-HCH-3 study of VOXZOGO in children with hypochondroplasia met its primary endpoint, with a statistically significant increase in annualized growth velocity (AGV) at week 52 versus placebo (LS mean difference +2.33 cm/yr, p<0.0001)" [source](https://www.sec.gov/Archives/edgar/data/1048477/000104847726000015/earningsrelease-6aug26ex991.htm) **The record says:** ClinicalTrials.gov lists the trial (NCT06455059) with an estimated enrollment of 80, a primary outcome of "Change from baseline in annualized growth velocity (AGV) at Week 52 versus placebo", and a quadruple-masked randomized design. The release also cites a Phase 2 investigator-sponsored extension in 13 children. [source](https://clinicaltrials.gov/study/NCT06455059) **Our view:** The result is placebo-controlled and statistically clear. It is still a one-year growth velocity measure in about 80 children, and the supporting long-term data come from 13. Final adult height is not what was tested. 5. Science · weight medium U.S. Voxzogo approval is accelerated and the fix is open-label **The company said:** "In July, BioMarin announced that the FDA accepted its sNDA for full approval of VOXZOGO in children with achondroplasia, with a Prescription Drug User Fee Act (PDUFA) target action date of February 28, 2027." [source](https://www.sec.gov/Archives/edgar/data/1048477/000104847726000015/earningsrelease-6aug26ex991.htm) **The record says:** The 10-Q says "GALAFOLD and VOXZOGO are approved in the U.S. under accelerated approval and are subject to post-marketing requirements to obtain full approval" and "To fulfill this post-marketing requirement, we intend to use our ongoing open-label extension studies compared to available natural history." [source](https://www.sec.gov/Archives/edgar/data/1048477/000104847726000016/bmrn-20260630.htm) **Our view:** The release frames February 2027 as a date for full approval. The filing adds that continued approval is contingent on confirmatory evidence, and that the evidence plan is open-label extensions against natural history. Voxzogo is roughly a quarter of quarterly revenue, so this date matters. 6. Legal and disclosure record · weight low DOJ subpoena on testing programs, no securities litigation **The record says:** The 10-Q reports that BioMarin "received a subpoena from the U.S. Department of Justice (DOJ) requesting that the Company produce certain documents regarding sponsored testing programs relating to VIMIZIM and NAGLAZYME", first disclosed in the 2023 10-K, that it is cooperating, and that it cannot give assurances about the outcome. Item 1, Legal Proceedings, reads "None." No securities litigation is disclosed in the latest filing. [source](https://www.sec.gov/Archives/edgar/data/1048477/000104847726000016/bmrn-20260630.htm) **Our view:** The subpoena is a documented, unresolved inquiry, now more than two years old. It concerns two older enzyme products, not Voxzogo, and no charge or finding is disclosed. Documents we compared - [Q2 2026 earnings release (8-K Ex. 99.1)](https://www.sec.gov/Archives/edgar/data/1048477/000104847726000015/earningsrelease-6aug26ex991.htm) 2026-08-06 - [Form 10-Q for the quarter ended June 30, 2026](https://www.sec.gov/Archives/edgar/data/1048477/000104847726000016/bmrn-20260630.htm) 2026-08-06 - [8-K Item 2.02, estimated Alesta financial impact](https://www.sec.gov/Archives/edgar/data/1048477/000104847726000019/bmrn-20261006.htm) 2026-10-06 - [8-K Item 8.01, discontinuation of Voxzogo in Noonan syndrome](https://www.sec.gov/Archives/edgar/data/1048477/000162828026061973/bmrn-20260915.htm) 2026-09-15 - [Press release: Alesta Therapeutics acquisition (8-K Ex. 99.1)](https://www.sec.gov/Archives/edgar/data/1048477/000119312526354780/d172628dex991.htm) 2026-08-18 - [ClinicalTrials.gov NCT06455059 (CANOPY-HCH-3)](https://clinicaltrials.gov/study/NCT06455059) 2026-01-20 This is opinion. We compare the company's own announcements with its filings and the scientific record, and link every source. It is not an allegation of wrongdoing and not investment or legal advice. Legal items list only matters disclosed in filings or by courts and regulators. Checked Oct 23, 2026. Companies can respond through our [right of reply](https://aibio.space/reputation/#reply). ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:BMRN on TradingView](https://www.tradingview.com/symbols/NASDAQ-BMRN/). ## SEC filings and registration - **SEC name**: Biomarin Pharmaceutical Inc - **CIK**: 1048477 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: BMRN (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Large accelerated filer - **Business address**: 105 DIGITAL DRIVE, NOVATO, CA, 94949 - **Phone**: 4155066700 - **Shares outstanding**: 193,573,759 as of 2026-07-28 (10-Q filed 2026-08-06) ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1048477/000104847726000019/bmrn-20261006.htm) filed 2026-10-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1048477/000162828026063981/bmrn-20260924.htm) filed 2026-09-30 - [8-K](https://www.sec.gov/Archives/edgar/data/1048477/000162828026061973/bmrn-20260915.htm) filed 2026-09-15 - [8-K](https://www.sec.gov/Archives/edgar/data/1048477/000162828026061717/bmrn-20260910.htm) filed 2026-09-14 - [8-K](https://www.sec.gov/Archives/edgar/data/1048477/000119312526377696/d110660d8k.htm) filed 2026-09-01 - [8-K](https://www.sec.gov/Archives/edgar/data/1048477/000119312526375275/d110137d8k.htm) filed 2026-08-31 - [8-K](https://www.sec.gov/Archives/edgar/data/1048477/000119312526354780/d172628d8k.htm) filed 2026-08-18 - [10-Q](https://www.sec.gov/Archives/edgar/data/1048477/000104847726000016/bmrn-20260630.htm) filed 2026-08-06 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001048477), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/biomarin-pharmaceutical/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "BioMarin Pharmaceutical (BMRN): news, pipeline and catalysts", 2026-10-31, https://aibio.space/companies/biomarin-pharmaceutical/